Article
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
Cancer chemotherapy and pharmacology - 1 Feb 2021
Verheijen R B, van Duijl T T, van den Heuvel M M, Vessies D, Muller M, Beijnen J H, Janssen J M, Schellens J H M, Steeghs N, van den Broek D, Huitema A D R
Abstract excerpt
PURPOSE: We studied EGFR mutations in circulating tumor DNA (ctDNA) and explored their role in predicting the progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients treated with erlotinib or gefitinib. METHODS: The L858R, T790M mutations and exon 19 deletions were quantified in plasma using digital droplet polymerase chain reaction (ddPCR). The dynamics of ctDNA mutations over time and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.